Chinese clinical-stage biopharma Worg closes $152m Series C round

Worg Pharmaceuticals, a Chinese clinical-stage biopharmaceutical firm with a focus on immunotherapies, has raised over 1.1 billion yuan ($151.7 million) in a Series C round of financing from domestic and overseas investors, according to a statement on Thursday.